Reuters: Regulatory News: UPDATE 1-XenoPort to drop multiple sclerosis drug after trial failure

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-XenoPort to drop multiple sclerosis drug after trial failure May 20th 2013, 11:12 Mon May 20, 2013 7:12am EDT May 20 (Reuters) - XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo. The company said it will shut down all activities related to the drug, arbaclofen placarbil, and planned to provide an update on the impact of the expected savings. The drug did not show statistical significance compared to the placebo on two clinical scales - severity of symptoms and response to treatment, and spasticity. The drug, which was intended to treat spasticity, stiffness and involuntary multiple spasms, was tested on 228 multiple sclerosis patients in the United States. Dosages of 30 mg and 45 mg of the drug administered twice a day were compared to the placebo group. Xenoport said seven subjects experienced adverse events, none of which were related to the treatment. Shares of the company closed at $6.75 on the Nasdaq on Friday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions